Kanada - Kiingereza - Health Canada

fresenius kabi canada ltd - heparin sodium - solution - 10000unit - heparin sodium 10000unit - heparins

Marekani - Kiingereza - NLM (National Library of Medicine)

golden state medical supply, inc. - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 1 mg

Marekani - Kiingereza - NLM (National Library of Medicine)

auromedics pharma llc - oxacillin sodium (unii: g0v6c994q5) (oxacillin - unii:uh95vd7v76) - oxacillin 2 g - oxacillin is indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug. (see clinical pharmacology - susceptibility test methods .) oxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. oxacillin should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus , therapy should not be continued with oxacillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of oxacillin for injection, usp and other antibacterial drugs, oxacillin for injection, usp should be used only to treat or prevent infections that are proven or str

Marekani - Kiingereza - NLM (National Library of Medicine)

mylan institutional llc - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd) - ampicillin 10 g in 100 ml - ampicillin for injection, usp is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: respiratory tract infections caused by streptococcus pneumoniae , staphylococcus aureus (penicillinase and nonpenicillinase-producing), h. influenzae , and group a beta-hemolytic streptococci. bacterial meningitis caused by e. coli , group b streptococci, and other gram-negative bacteria (listeria monocytogenes, n. meningitidis ). the addition of an aminoglycoside with ampicillin may increase its effectiveness against gram-negative bacteria. septicemia and endocarditis caused by susceptible gram-positive organisms including streptococcus spp., penicillin g-susceptible staphylococci, and enterococci. gram-negative sepsis caused by e. coli, proteus mirabilis and salmonella spp. responds to ampicillin. endocarditis due to enterococcal strains usually respond to intravenous therapy. the addition of an aminoglycoside may enhance the effectiveness of

Marekani - Kiingereza - NLM (National Library of Medicine)

a-s medication solutions - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules usp and other antibacterial drugs, dicloxacillin sodium capsules usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility plate testing ). dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal in

Kanada - Kiingereza - Health Canada

fresenius kabi canada ltd - heparin sodium - solution - 10000unit - heparin sodium 10000unit - heparins

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - piperacillin sodium; tazobactam (as sodium salt) - powder for solution for infusion - 2/0.25 gram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; piperacillin and enzyme inhibitor

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - piperacillin sodium; tazobactam (as sodium salt) - powder for solution for infusion - 4/0.5 gram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; piperacillin and enzyme inhibitor

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - piperacillin sodium (equivalent: piperacillin, qty 4000 mg) - injection, powder for - excipient ingredients: - piperacillin sodium is indicated for treatment of systemic and local infections due to susceptible gram-negative and gram-positive aerobic and anaerobic bacteria. its efficacy has also been demonstrated in infections caused by some carbenicillin resistant organisms. appropriate cultures should be made before initiating treatment. therapy may be started while awaiting results of susceptibility testing. treatment should be adjusted, if necessary, when results of testing become available. piperacillin sodium is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and urinary tract) procedures, vaginal hysterectomy, and caesarean section. efficacy has not been demonstrated in biliary tract procedures. effective prophylaxis depends on the time of administration; piperacillin sodium should be given 1/2 to 1 hour before the operation so that effecitve levels can be achieved in the wound prior to the procedure. the exception to this rule is in caesarean section where pipercillin sodium should be administered after clamping the umbilical cord. types of infection: piperacillin sodium is recommended for the treatment of the following types of infection caused by one or more susceptible pathogens. severe systemic infections; including bacterial septicaemia, endocarditis. genitourinary tract infections (complicated and uncomplicated), including urethritis, cystitis and pyelonephritis. it is also effective in acute, uncomplicated infections caused by neisseria gonorrhoeae. respiratory tract infections ( acute and chronic), including bronchitis, pneumonia, empyema and lung abscess. in patients with chronic respiratory infections of cystic fibrosis, clinical improvement has been achieved but bacterial eradication may not occur. ear, nose, throat and oral cavity infections. intra-abdominal infections, including those of the biliary tract and intra-abdominal abscess. gynaecological and obstetric infections, including endometritis, pelvic abscess and inflammation, salpingitis and puerperal infections. skin and skin structure infections, including those following infected wounds and burns, surgery and trauma. bone and joint infections. piperacillin sodium should be used at reduced dosage in adults with severely restricted kidney function (see dosage and administration). combined therapy with other antibiotics. aminoglycosides. based on in-vitro synergism and clinical results, combined therapy with piperacillin and aminoglycoside antibiotics (eg amikacin) may be used in the treatment of serious infections caused by such organisms as klebsiella, indole-positive proteus, pseudomonas and serratia. both piperacillin and the respective aminoglycoside should be given at the full therapeutic dose. cephalosporins. if piperacillin sodium is proposed to be administered concomitantly with a cephalosporin, an additive, synergistic or antagonistic antibacterial action of the two antibiotics should first be ascertained through in-virtro tests. based on in-vitro data, cefoxitin should not be given with piperacillin. piperacillin sodium has not been shown to be physically compatible with cephalosporins when mixed in the same infusion fluid. note: whenever piperacillin sodium is administered concurrently with another antibiotic, they should not be mixed in the same solution but must be administered separately.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - piperacillin sodium (equivalent: piperacillin, qty 2000 mg) - injection, powder for - excipient ingredients: - piperacillin sodium is indicated for the treatment of systemic and local infections due to susceptible gram-negative and gram-positive aerobic and anaerobic bacteria. its efficacy has also been demonstrated in infections caused by some carbenicillin resistant organisms. appropriate cultures should be made before initiating treatment. therapy may be started while awaiting results of susceptibility testing. treatment should be adjusted, if necessary, when results of testing become available. piperacillin sodium is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and urinary tract) procedures, vaginal hysterectomy, and caesarean section. efficacy has not been demonstrated in biliary tract procedures. effective prophylaxis depends on the time of administration; piperacillin sodium should be given 1/2 to 1 hour before the operation so that effective levels can be achieved in the wound prior to the procedure. the exception to this rule is in caesarean section where piperacillin sodium should be administered after clamping the umbilical cord. types of infection: piperacillin sodium is recommended for the treatment of the following types of infection caused by one or more susceptible pathogens. severe systemic infections, including bacterial septicaemia, endocarditis. genitourinary tract infections (complicated and uncomplicated), including urethritis, cystitis and pyelonephritis. it is also effective in acute, uncomplicated infections caused by neisseria gonorrhoeae. respiratory tract infections (acute and chronic), including bronchitis, pneumonia, empyema and lung abscess. in patients with chronic respiratory infections or cystic fibrosis, clinical improvement has been achieved but bacterial eradication may not occur. ear, nose, throat and oral cavity infections. intra-abdominal infections, including those of the biliary tract and intra-abdominal abscess. gynaecological and obstetric infections, including endometritis, pelvic abscess and inflammation, salpingitis and puerperal infections. skin and skin structure infections, including those following infected wounds and burns, surgery and trauma. bone and joint infections. piperacillin sodium should be used at reduced dosage in adults with severely restricted kidney function (see dosage and administration). combined therapy with other antibiotics. aminoglycosides. based on in-vitro synergism and clinical results, combined therapy with piperacillin and aminoglycoside antibiotics (eg amikacin) may be used in the treatment of serious infections caused by such organisms as klebsiella, indole-positive proteus, pseudomonas and serratia. both piperacillin and the respective aminoglycoside should be given at the full therapeutic dose. cephalosporins. if piperacillin sodium is proposed to be administered concomitantly with a cephalosporin, and additive, synergisitc or antagonistic antibacterial action of the two antibiotics should first be ascertained through in-vitro tests. based on in-vitro data, cefoxitin should not be given with piperacillin. piperacillin sodium has not been shown to be physically compatible with cephalosporins when mixed in the same infusion fluid. note: whenever piperacillin sodium is administered concurrently with another antibiotic, they should not be mixed in the same solution but must be administered separately.